{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:34:40Z","timestamp":1791282880656,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Real-world data (RWD) has been a valuable addition to the scientific literature regarding treatment pathways, clinical outcomes and characteristics of patients with retinal diseases in recent years. Registries, observational studies and patient databases are often used for real-world research. However, there is limited information for each data source on the design, consistency, data captured, limitations and usability for assessing research questions. Using a systematic approach, we identified RWD sources for patients with retinal diseases and assessed them for completeness of data relating to different outcomes.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic literature review was carried out to identify RWD sources for patients with retinal disease. Potentially relevant articles published between 2006 and 2016 were screened following electronic searches in Embase and MEDLINE. Congress and supplementary searches were undertaken to identify RWD sources that may not be referenced in full publications. For each data source, availability and quantity of data on baseline status, clinical outcomes, treatment and management, safety, and patient-reported and economic burden were assessed using a bespoke completeness assessment tool based on International Consortium for Health Outcomes Measurement guidelines for macular degeneration. Completeness of data for each area of interest in each data source was assessed and rated using a \u2018good\u2013moderate\u2013poor\u2019 rating system based on availability and quantity of available data. Each data source was then given an overall score based on its score for each of the 7 areas of interest.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 128 RWD sources from 32 countries were identified. Of the identified sources, 64 sources from 16 countries of interest were analyzed. Most of these sources provided information on baseline status and clinical outcomes and treatment, but few collected data on economic and patient-reported burden. Of the RWD sources analyzed, 10 scored highly in the overall completeness assessment, collecting data on most or all of the areas of interest; these sources are considered to be robust data sources for performing ophthalmology real-world studies.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The study provides a comprehensive list of RWD sources for patients with retinal disease, many of which will be useful for conducting real-world studies in the field of ophthalmology.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-019-1208-9","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T12:07:53Z","timestamp":1571227673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy \u2013 a systematic approach to identify and characterize data sources"],"prefix":"10.1186","volume":"19","author":[{"given":"Vincent","family":"Daien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora M.","family":"Eldem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Talks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Korobelnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Finger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaro","family":"Evuarherhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"1208_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","volume":"157","author":"TY Wong","year":"2014","unstructured":"Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157:9\u201325 e12.","journal-title":"Am J Ophthalmol"},{"key":"1208_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106\u201316.","journal-title":"Lancet Glob Health"},{"key":"1208_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3129\/i07-153","volume":"42","author":"A Cruess","year":"2007","unstructured":"Cruess A, Zlateva G, Xu X, Rochon S. Burden of illness of neovascular age-related macular degeneration in Canada. Can J Ophthalmol. 2007;42:836\u201343.","journal-title":"Can J Ophthalmol"},{"key":"1208_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Yau","year":"2012","unstructured":"Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556\u201364.","journal-title":"Diabetes Care"},{"key":"1208_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/archopht.116.4.514","volume":"116","author":"RA Williams","year":"1998","unstructured":"Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998;116:514\u201320.","journal-title":"Arch Ophthalmol"},{"key":"1208_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1471-2415-14-78","volume":"14","author":"SR Dawson","year":"2014","unstructured":"Dawson SR, Mallen CD, Gouldstone MB, Yarham R, Mansell G. The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data. BMC Ophthalmol. 2014;14:78.","journal-title":"BMC Ophthalmol"},{"key":"1208_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10792-016-0296-2","volume":"37","author":"RK Kuriakose","year":"2017","unstructured":"Kuriakose RK, Khan Z, Almeida DRP, Braich PS. Depression and burden among the caregivers of visually impaired patients: a systematic review. Int Ophthalmol. 2017;37:767\u201377.","journal-title":"Int Ophthalmol"},{"key":"1208_CR8","doi-asserted-by":"publisher","first-page":"e101072","DOI":"10.1371\/journal.pone.0101072","volume":"9","author":"P Mitchell","year":"2014","unstructured":"Mitchell P, Bressler N, Doan QV, Dolan C, Ferreira A, Osborne A, et al. Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. PLoS One. 2014;9:e101072.","journal-title":"PLoS One"},{"key":"1208_CR9","doi-asserted-by":"publisher","first-page":"e011504","DOI":"10.1136\/bmjopen-2016-011504","volume":"6","author":"DJ Taylor","year":"2016","unstructured":"Taylor DJ, Hobby AE, Binns AM, Crabb DP. How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. BMJ Open. 2016;6:e011504.","journal-title":"BMJ Open"},{"key":"1208_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0039-6257(03)00030-4","volume":"48","author":"J Ambati","year":"2003","unstructured":"Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257\u201393.","journal-title":"Surv Ophthalmol"},{"key":"1208_CR11","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"1208_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1517\/14728210902824141","volume":"14","author":"J Beutel","year":"2009","unstructured":"Beutel J, Rudolf M, Grisanti S. Current and future therapies for age-related macular degeneration. Expert Opin Emerg Drugs. 2009;14:341\u201362.","journal-title":"Expert Opin Emerg Drugs"},{"key":"1208_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4103\/0301-4738.36474","volume":"55","author":"S Grisanti","year":"2007","unstructured":"Grisanti S, Ziemssen F. Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol. 2007;55:417\u201320.","journal-title":"Indian J Ophthalmol"},{"key":"1208_CR14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1755-3768.2007.00979.x","volume":"85","author":"UM Schmidt-Erfurth","year":"2007","unstructured":"Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcostegui B, et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007;85:486\u201394.","journal-title":"Acta Ophthalmol Scand"},{"key":"1208_CR15","unstructured":"Compendium EM. Lucentis 10 mg\/ml solution for injection - Summary of Product Characteristics. Available from: \n                    https:\/\/www.medicines.org.uk\/emc\/medicine\/19409\n                    \n                   (Accessed 8 Dec 2017)."},{"key":"1208_CR16","unstructured":"Compendium EM. Eylea 40mg\/ml solution for injection in a vial - Summary of Product Characteristics. Available from: \n                    https:\/\/www.medicines.org.uk\/emc\/medicine\/27224\n                    \n                   (Accessed 8 Dec 2017)."},{"key":"1208_CR17","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMp1614720","volume":"376","author":"M Najafzadeh","year":"2017","unstructured":"Najafzadeh M, Schneeweiss S. From trial to target populations - calibrating real-world data. N Engl J Med. 2017;376:1203\u20135.","journal-title":"N Engl J Med"},{"key":"1208_CR18","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375:2293\u20137.","journal-title":"N Engl J Med"},{"key":"1208_CR19","doi-asserted-by":"crossref","unstructured":"Atchison EA, Wood KM, Mattox CG, Barry CN, Lum F, MacCumber MW. The real-world effect of intravitreous anti-vascular endothelial growth factor drugs on intraocular pressure: an analysis using the IRIS registry. Ophthalmology. 2018;125:676\u201382.","DOI":"10.1016\/j.ophtha.2017.11.027"},{"key":"1208_CR20","doi-asserted-by":"publisher","first-page":"e0189035","DOI":"10.1371\/journal.pone.0189035","volume":"12","author":"T Hanemoto","year":"2017","unstructured":"Hanemoto T, Hikichi Y, Kikuchi N, Kozawa T. The impact of different anti-vascular endothelial growth factor treatment regimens on reducing burden for caregivers and patients with wet age-related macular degeneration in a single-center real-world Japanese setting. PLoS One. 2017;12:e0189035.","journal-title":"PLoS One"},{"key":"1208_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","volume":"65","author":"H Mehta","year":"2018","unstructured":"Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127\u201346.","journal-title":"Prog Retin Eye Res"},{"key":"1208_CR22","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;6:e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"1208_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2016.04.012","volume":"168","author":"IA Rodrigues","year":"2016","unstructured":"Rodrigues IA, Sprinkhuizen SM, Barthelmes D, Blumenkranz M, Cheung G, Haller J, et al. Defining a minimum set of standardized patient-centered outcome measures for macular degeneration. Am J Ophthalmol. 2016;168:1\u201312.","journal-title":"Am J Ophthalmol"},{"key":"1208_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12882-015-0028-2","volume":"16","author":"FX Liu","year":"2015","unstructured":"Liu FX, Rutherford P, Smoyer-Tomic K, Prichard S, Laplante S. A global overview of renal registries: a systematic review. BMC Nephrol. 2015;16:31.","journal-title":"BMC Nephrol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-019-1208-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T23:19:38Z","timestamp":1602717578000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-019-1208-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1208"],"URL":"https:\/\/doi.org\/10.1186\/s12886-019-1208-9","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"12 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report consulting fees, travel support and financial and non-financial support outside the submitted work: V. Daien - Alcon, Bayer, Horus, Novartis and Thea; B. M. Eldem - Alcon, Allergan Novartis, Bayer, Baush & Lomb, Ophtotech, Pfizer, Roche, Sanofi, Santen, Servier and Thea; J. S. Talks - Allergan, Bayer and Novartis; J.-F. Korobelnik - Alcon, Bayer, Baush & Lomb, Beaver Visitec, Krys, Kanghing, NanoRetina, Novartis, Roche, Thea and Zeiss; P. Mitchell - Abbott, Allergan, Bayer, Genentech, Novartis and Roche; R. P. Finger - Bayer, Novartis, Novelion, Opthea, RetinaImplant and Santen; T. Sakamoto: Alcon, Bayer, Novartis, Santen, Senju and Wakamoto; T.Y. Wong - Abbott, Allergan, Bayer, Novartis, Pfizer and Roche; O. Evuarherhe is an employee of Oxford PharmaGenesis; G. Carter is an employee of Oxford PharmaGenesis; J. Carrasco is an employee of Bayer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}